Medicure Inc (TSE:MPH) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Medicure Inc. reported a decline in annual revenue from $23.1 million in 2022 to $21.7 million in 2023, with a net loss of $922,000 for the year, contrasting the previous year’s $1.4 million net income. The company’s flagship product, AGGRASTAT, also saw a decrease in sales, while Marley Drug’s pharmacy revenue increased. These financial results include non-cash expenses such as amortization and share-based compensation.
For further insights into TSE:MPH stock, check out TipRanks’ Stock Analysis page.